United States Health

Biohaven (NYSE:BHVN) will present updated Phase 1 data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026, covering the ongoing BHV1530-101 study.

Palatin Technologies (NASDAQ:PTN) reported fiscal 2026 collaboration and license revenue of $13.2 million, compared with zero revenue in fiscal 2025.

AN2 Therapeutics (NASDAQ:ANTX) received an extension of funding from the Gates Foundation to support its tuberculosis research collaboration with GSK focused on boron-based leucyl-tRNA synthetase inhibitors.

Eton Pharmaceuticals (NASDAQ:ETON) launched IMPAVIDO (miltefosine) capsules in the United States under exclusive U.S. commercialization rights for the treatment of certain forms of leishmaniasis.

Pfizer (NYSE:PFE) announced it will present data from 45 oncology research abstracts at the European Society for Medical Oncology Congress 2026, taking place October 23–27 in Madrid, Spain.

Eli Lilly (NYSE:LLY) launched the Change the Course Commitment, an initiative aimed at increasing access to its diabetes and obesity medicines in resource-limited settings before 2040.

Kodiak Sciences (NASDAQ:KOD) reported that Zenkuda and tabirafusp-ted met primary vision endpoints in the Phase 3 DAYBREAK trial evaluating treatments for wet age-related macular degeneration.

Codexis (NASDAQ:CDXS) signed an agreement with an unnamed siRNA drug developer to explore stereo-defined fragment synthesis using its ECO Synthesis platform.

National Healthcare Properties (NYSE:NHP) agreed to sell 40 outpatient medical facilities for approximately $531 million, with closing expected in the fourth quarter of 2026.

MediciNova (NASDAQ:MNOV) reported topline results from a Phase 2 placebo-controlled trial evaluating MN-001, also known as tipelukast, in patients with type 2 diabetes, fatty liver disease, and elevated triglycerides.

Zymeworks (NASDAQ:ZYME) completed its acquisition of Theravance Biopharma for $17 per share, adding rights to YUPELRI profit sharing and international royalties.

IDEAYA Biosciences (NASDAQ:IDYA) promoted Dr. Michael White from chief scientific officer to president of research and development, effective September 28, 2026.